Literature DB >> 21633527

Soluble ST2: a new and promising activity marker in ulcerative colitis.

David Díaz-Jiménez1, Lucía E Núñez, Caroll J Beltrán, Enzo Candia, Cristóbal Suazo, Manuel Alvarez-Lobos, María-Julieta González, Marcela A Hermoso, Rodrigo Quera.   

Abstract

AIM: To correlate circulating soluble ST2 (sST2) levels with the severity of ulcerative colitis (UC) and serum levels of pro-inflammatory cytokines, and to demonstrate the predictive power of sST2 levels for differentiation between active and inactive UC.
METHODS: We recruited 153 patients: 82 with UC, 26 with Crohn's disease (CD) and 43 disease controls [non-inflammatory bowel disease (IBD)]. Subjects were excluded if they had diagnosis of asthma, autoimmune diseases or hypertension. The serum levels of sST2 and pro-inflammatory cytokines [pg/mL; median (25th-75th)] as well as clinical features, endoscopic and histological features, were subjected to analyses. The sST2 performance for discrimination between active and inactive UC, non-IBD and healthy controls (HC) was determined with regard to sensitivity and specificity, and Spearman's rank correlation coefficient (r). To validate the method, the area under the curve (AUC) of receiver-operator characteristic (ROC) was determined (AUC, 95% CI) and the total ST2 content of the colonic mucosa in UC patients was correlated with circulating levels of sST2.
RESULTS: The serum sST2 value was significantly higher in patients with active [235.80 (90.65-367.90) pg/mL] rather than inactive UC [33.19 (20.04-65.32) pg/mL], based on clinical, endoscopic and histopathological characteristics, as well as compared with non-IBD and HC (P < 0.001). The median level of sST2 in CD patients was 54.17 (35.02-122.0) pg/mL, significantly higher than that of the HC group only (P < 0.01). The cutoff was set at 74.87 pg/mL to compare active with inactive UC in a multicenter cohort of patients. Values of sensitivity, specificity, and ability to correctly classify UC, according to activity, were 83.33%, 83.33% and 83.33%, respectively. The AUC of the ROC curve to assess the ability of this molecule to discriminate between active vs inactive UC was 0.92 (0.86-0.97, P < 0.0001). The serum levels of sST2 in patients with UC significantly correlated with endoscopic and histopathological scores (r = 0.76 and r = 0.67, P < 0.0001, respectively), and with the pro-inflammatory cytokine, tumor necrosis factor-α (r = 0.69 and r = 0.61, respectively, P < 0.0001). Interestingly, we found a direct correlation between total intestinal ST2 content and serum levels of sST2, adjusted to endoscopic activity score in patients with mild (r = 0.44, P = 0.004), moderate (r = 0.59, P = 0.002) and severe disease (r = 0.82, P = 0.002). Only patients with inactive UC showed no significant correlation (r = 0.45, P = 0.267).
CONCLUSION: sST2 levels correlated with disease severity and inflammatory cytokines, are able to differentiate active from inactive UC and might have a role as a biomarker.

Entities:  

Keywords:  Biomarkers; Inflammatory bowel disease; Soluble ST2; Ulcerative colitis

Mesh:

Substances:

Year:  2011        PMID: 21633527      PMCID: PMC3092869          DOI: 10.3748/wjg.v17.i17.2181

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  66 in total

Review 1.  [The role of anti-neutrophil cytoplasmic antibodies (ANCA) and anti-Saccharomyces cerevisiae antibodies (ASCA) in inflammatory bowel disease].

Authors:  J P Gisbert; F Gomollón; J Maté; J M Pajares
Journal:  Gastroenterol Hepatol       Date:  2003-05       Impact factor: 2.102

2.  Faecal calprotectin shedding after short-term treatment with non-steroidal anti-inflammatory drugs.

Authors:  T R Meling; L Aabakken; A Røseth; M Osnes
Journal:  Scand J Gastroenterol       Date:  1996-04       Impact factor: 2.423

3.  Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis.

Authors:  Luca Pastorelli; Rekha R Garg; Sharon B Hoang; Luisa Spina; Benedetta Mattioli; Melania Scarpa; Claudio Fiocchi; Maurizio Vecchi; Theresa T Pizarro
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-12       Impact factor: 11.205

4.  Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus.

Authors:  Mo Yin Mok; Fang Ping Huang; Wai Ki Ip; Yi Lo; Fung Yi Wong; Eric Yuk Tat Chan; Kwok Fai Lam; Damo Xu
Journal:  Rheumatology (Oxford)       Date:  2009-12-21       Impact factor: 7.580

Review 5.  Inflammatory bowel disease: genetic and epidemiologic considerations.

Authors:  Judy H Cho
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

6.  Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction.

Authors:  Domingo A Pascual-Figal; Jordi Ordoñez-Llanos; Pedro L Tornel; Rafael Vázquez; Teresa Puig; Mariano Valdés; Juan Cinca; Antoni Bayes de Luna; Antoni Bayes-Genis
Journal:  J Am Coll Cardiol       Date:  2009-12-01       Impact factor: 24.094

7.  Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis.

Authors:  James D Lewis; Shaokun Chuai; Lisa Nessel; Gary R Lichtenstein; Faten N Aberra; Jonas H Ellenberg
Journal:  Inflamm Bowel Dis       Date:  2008-12       Impact factor: 5.325

8.  Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load.

Authors:  Jozef Bartunek; Leen Delrue; Frederik Van Durme; Olivier Muller; Filip Casselman; Bart De Wiest; Romaric Croes; Sofie Verstreken; Marc Goethals; Herbert de Raedt; Jaydeep Sarma; Lija Joseph; Marc Vanderheyden; Ellen O Weinberg
Journal:  J Am Coll Cardiol       Date:  2008-12-16       Impact factor: 24.094

9.  Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia.

Authors:  Paul J Limburg; Mary E Devens; Jonathan J Harrington; Nancy N Diehl; Douglas W Mahoney; David A Ahlquist
Journal:  Am J Gastroenterol       Date:  2003-10       Impact factor: 10.864

Review 10.  Laboratory markers in IBD: useful, magic, or unnecessary toys?

Authors:  S Vermeire; G Van Assche; P Rutgeerts
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

View more
  23 in total

Review 1.  Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy.

Authors:  Weiwei Jiang; Xuhang Li
Journal:  Mol Diagn Ther       Date:  2015-06       Impact factor: 4.074

Review 2.  Emerging role of interleukin-33 in autoimmune diseases.

Authors:  Cheng Pei; Mark Barbour; Karen J Fairlie-Clarke; Debbie Allan; Rong Mu; Hui-Rong Jiang
Journal:  Immunology       Date:  2014-01       Impact factor: 7.397

3.  IL-33 Signaling in Lung Injury.

Authors:  Jing Chang; Yue-Feng Xia; Ma-Zhong Zhang; Li-Ming Zhang
Journal:  Transl Perioper Pain Med       Date:  2016

4.  Platelet Activation Markers Are Associated with Crohn's Disease Activity in Patients with Low C-Reactive Protein.

Authors:  Hiroshi Takeyama; Tsunekazu Mizushima; Hideki Iijima; Shinzaki Shinichiro; Mamoru Uemura; Junichi Nishimura; Taishi Hata; Ichiro Takemasa; Hirofumi Yamamoto; Yuichiro Doki; Masaki Mori
Journal:  Dig Dis Sci       Date:  2015-06-16       Impact factor: 3.199

5.  Noninvasive Markers of Disease Activity in Inflammatory Bowel Disease.

Authors:  Raluca Vrabie; Sunanda Kane
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-09

6.  IL-33trap is a novel IL-33-neutralizing biologic that inhibits allergic airway inflammation.

Authors:  Aurora Holgado; Harald Braun; Elien Van Nuffel; Sammy Detry; Martijn J Schuijs; Kim Deswarte; Karl Vergote; Mira Haegman; Griet Baudelet; Jurgen Haustraete; Hamida Hammad; Bart N Lambrecht; Savvas N Savvides; Inna S Afonina; Rudi Beyaert
Journal:  J Allergy Clin Immunol       Date:  2019-03-13       Impact factor: 10.793

7.  Activated mast cells synthesize and release soluble ST2-a decoy receptor for IL-33.

Authors:  Geethani Bandara; Michael A Beaven; Ana Olivera; Alasdair M Gilfillan; Dean D Metcalfe
Journal:  Eur J Immunol       Date:  2015-09-09       Impact factor: 5.532

8.  From proteomics to discovery of first-in-class ST2 inhibitors active in vivo.

Authors:  Abdulraouf M Ramadan; Etienne Daguindau; Jason C Rech; Krishnapriya Chinnaswamy; Jilu Zhang; Greg L Hura; Brad Griesenauer; Zachary Bolten; Aaron Robida; Martha Larsen; Jeanne A Stuckey; Chao-Yie Yang; Sophie Paczesny
Journal:  JCI Insight       Date:  2018-07-26

9.  ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease.

Authors:  Jilu Zhang; Abdulraouf M Ramadan; Brad Griesenauer; Wei Li; Matthew J Turner; Chen Liu; Reuben Kapur; Helmut Hanenberg; Bruce R Blazar; Isao Tawara; Sophie Paczesny
Journal:  Sci Transl Med       Date:  2015-10-07       Impact factor: 17.956

Review 10.  Role of Interleukin-1 Receptor-Like 1 (ST2) in Cerebrovascular Disease.

Authors:  Cristina Sastre; Matthew B Bevers; W Taylor Kimberly
Journal:  Neurocrit Care       Date:  2021-07-06       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.